Salim Ben Yahia, Rim Kahloun, Salma Gargouri, Rim Ghrissi, Riadh Messaoud, Moncef Khairallah (Monastir, Tunisia)


To manage choroidal neovascularization (CNV) secondary to angioid streaks with intravitreal injection of bevacizumab.


Eight eyes of 8 patients with CNV secondary to angioid streaks were treated with intravitreal injection of 1.25 mg (0.05 mL) of bevacizumab. Main outcome measures included changes in best-corrected visual acuity, optical coherence tomography features, and leakage on fluorescein angiography. Mean follow-up was 10 months.

Effectiveness / Safety:

Visual acuity improved from 20/200 at presentation to 20/63 at the last follow-up visit.  Complete closure of CNV, without recurrences during the follow-up period, occurred in 5 eyes (62.5%). Recurrences of CNV were noted in 3 eyes (37.5%), requiring a second injection for one patient, 2 injections for the second patient, and 3 injections for the third patient. No ocular or systemic side effects were observed.

Take home message:

Intravitreal bevacizumab therapy seems to be a safe and effective treatment for choroidal neovascularization secondary to angioid streaks. As observed with other therapeutic options, recurrences were not rare.